home All News open_in_new Full Article

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S. Partnership supports Teva’s Pivot to Growth strategy and adds to its broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) — Samsung […]


today 8 hours ago attach_file Culture
attach_file Other
attach_file Politics
attach_file Society
attach_file Economics
attach_file Sport
attach_file Other
attach_file Politics
attach_file Society
attach_file Economics
attach_file Culture
attach_file Other
attach_file Society
attach_file Culture
attach_file Other
attach_file Culture
attach_file Other
attach_file Culture
attach_file Other


ID: 15940960
Add Watch Country

arrow_drop_down